Searched for
SORAFENIB
Experts flag UK-India FTA over patent terms, access to drugsConcerns are mounting in India over the UK-India Free Trade Agreement's potential impact on access to affordable medicines. Experts fear th...- CDSCO approves AstraZeneca's anti-liver cancer drug combinationThe primary endpoint was overall survival (OS) for the combination versus sorafenib and secondary endpoints included OS for durvalumab vers...
- Hyderabad-based Natco Pharma wants to make Eli Lilly’s Covid drugNatco has sought nod for the manufacture and marketing of baricitinib bulk drug and tablets in 1 to 4 mg versions in India. This move may t...
- Delhi High Court favours Natco, Alembic; allows them to export generics of Bayer's drugsBayer had approached court in 2016 to stop Alembic Pharmaceuticals from exporting its generic of the German company's blood thinner brand '...
- Natco Pharma's partner MylanInc gets USFDA nod for cancer drugThe company's marketing partner Mylan Inc has received a tentative approval from the United States Food and Drug Administration (USFDA).
- High Court rejects AstraZeneca’s diabetes drug pleaThe Delhi High Court has dismissed AstraZeneca’s plea to block Hyderabadbased Lee Pharma from making copies of its anti-diabetes drug Ongly...
- Natco Pharma's US partner Mylan files application with USFDANatco Pharma's marketing partner Mylan Inc has filed an application with the US health regulator for generic Sorafenib tablets used mainly ...
- Indian patent and pharma laws should not be considered discriminatory: Public CitizenIn a submission to US International Trade Commission, 'Public Citizen' said that India's rules meet the data protection requirements.
- Bayer demands withdrawal of Natco Pharma's compulsory licenceIn March, India allowed Natco Pharma to legally make and sell a low-cost version of cancer drug Nexavar at 3% of the original medicine's pr...
- Cipla breached patent rights by slashing cancer drug price: Bayer PharmaBayer has not given its consent to Cipla to launch its generic Sorafenib & co's decision to cut price "is clear patent infringement," Bayer...
- Patented drugs: No application pending for compulsory license, says governmentAmid concerns that more domestic pharma companies could seek compulsory licenses to replicate patented drugs, the government said no such a...
- Cipla shocks rivals by slashing cancer drug prices up to 75%Kidney cancer drug will now be available at Rs 6,840 for a month's supply, down from Rs 28,000. Lung cancer drug will cost Rs 4,250, down f...
- Natco victory could encourage other generic companies also to apply for compulsory licenceEarlier this week, a ruling effectively cut the price of high-cost cancer drug Sorafenib by 97%. But that’s just one of many legal battles ...
- Should compulsory licensing be allowed?The CL on sorafenib does not only help cancer patients, it also is a step towards building domestic manufacturing capacity and knowhow in a...
- Natco Pharma files India's first compulsory licence pleaNatco Pharma has applied for the country's first compulsory licence to sell a generic version of Bayer's patented medicine.
- Natco may seek compulsory licence for Bayer's cancer drugNatco Pharma plans to seek a compulsory licence to make Bayer AG's Nexavar in India, invoking a provision in local laws that allows generic...
- Bayer drags Cipla to court over patentGerman drugmaker Bayer has filed a patent infringement case against Cipla, the largest domestic drug seller, to stop the Mumbai-based compa...
- Cipla's clone of Bayer cancer drug gets nodThis case was keenly watched by both pharma industry and health activists because it had much wider ramifications.
- Cipla opposes patent for GSK’s cancer drugCipla has filed a grant opposition in the Kolkata patent office against GSK's newly-launched breast cancer drug on grounds of obviousness a...
- New approach to "re-sensitize" treatment resistant tumoursResearchers from Georgetown University Medical Centre have suggested a new approach that can "re-sensitize" tumours, which have become resi...
Load More
